Clinical trial
A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced…
NCT00476554 · Cyclacel Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00476554 |
|---|---|
| Title | A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma |
| Official title | A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma |
| Lead sponsor | Cyclacel Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cutaneous T-cell Lymphoma (CTCL) |
| Intervention type | Drug |
| Interventions | Sapacitabine |
| Enrollment | 16 |
| Start date | Apr 1, 2007 |
| Primary completion | Mar 1, 2012 |
| Completion | Mar 1, 2012 |
| First posted | May 22, 2007 |
| Last update posted | Dec 22, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: